Hospira woes continue as GSK sues over quality failures
March 5, 2013Manufacturing and Production GSK, Hospira
The difficulties besetting generic firm and contract manufacturer Hospira have taken a new turn with the news that one of …
Nicholson faces down critics
March 5, 2013Medical Communications, Sales and Marketing Mid Staffs, NHS, Nicholson
Sir David Nicholson, chief executive of the NHS, has been involved in testy exchanges with MPs at the House of …
Capsugel cuts deal to buy Scotland’s Encap
March 5, 2013Manufacturing and Production Capsugel, encap
Capsugel has bought Scotland’s Encap Drug Delivery in yet another bout of merger & acquisition (M&A) activity in the capsule …
NHS Commissioning Board appoints new director of Patient Experience
March 4, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CB, Churchill, NHS, UK
The NHS Commissioning Board has appointed Neil Churchill as the director of Patient Experience. In this new role Churchill will ensure that improving patient …
IPEC Americas takes aim at atypical visible particles
March 4, 2013Manufacturing and Production AVP, IPEC Americas
The industry body representing excipient users and suppliers in the US has set up a working group to tackle the …
Risk-assessment for excipients: guideline out for comment
March 4, 2013Manufacturing and Production GMP, risk
The European Commission has published its long-awaited risk-assessment guideline for determining the level of Good Manufacturing Practice (GMP) needed for …
EU approval for Ilaris
March 4, 2013Sales and Marketing Ilaris, Novartis
Novartis’ Ilaris has become the first biologic approved by the European Commission to treat patients suffering acute gouty arthritis attacks …
Zaltrap launched in UK
March 4, 2013Sales and Marketing Sanofi, Zaltrap
Sanofi and Regeneron Pharmaceuticals’ bowel cancer drug Zaltrap has been launched in the UK today. Zaltrap (aflibercept) will be used …
Boehringer targets AML
March 1, 2013Research and Development, Sales and Marketing AML, Boehringer
Boehringer Ingelheim is to begin a pivotal trial of its investigative treatment volasertib in patients with acute myeloid leukaemia (AML). …
Lundbeck booze pill for EU
March 1, 2013Sales and Marketing Lundbeck, alcohol, selincro
Lundbeck’s novel pill Selincro has been given European marketing authorisation to help patients with a drink problem to cut down. …
RSA welcomes pan-European consultant
February 28, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing rsa
Life sciences executive search and interim management firm RSA has announced that Dr Theo de Roij has joined the pan-European …
Eliquis approved by NICE
February 28, 2013Sales and Marketing BMS, Eliquis, NICE, Pfizer
In a move which will cheer Bristol-Myers Squibb and Pfizer, NICE has recommended oral blood-thinner Eliquis for use on the …
ABPI moves to improve compliance
February 28, 2013Sales and Marketing ABPI, NHS, alltrials, goldaccre, whiehead
The ABPI has fired its latest salvo in the clinical trial transparency debate by announcing it will appoint a new …
UCB warns of data ‘voyeurism’
February 27, 2013Research and Development, Sales and Marketing EFPIA, UCB, VBP, transparancy
UCB chief executive Roch Doliveux has attacked the idea of making all clinical trial data publicly available, saying it could …
Roche increases data access
February 27, 2013Research and Development, Sales and Marketing ABPI, BMJ, Goldacre, Roche
Roche has launched a new process designed to enable greater access to its clinical trial data for researchers from outside …
The King’s Fund’s Anna Dixon joins Department of Health
February 27, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dixon, NHS, king's fund
Director of Policy at The King’s Fund Dr Anna Dixon will be joining the Department of Health in early May …
Ben Goldacre versus Stephen Whitehead – PharmaTimes Debate
February 27, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, BMJ, Bad pharma, Cochrane, Goldacre, Whitehead
In the end, the ‘head to head’ between the UK’s most high profile critic of the pharma industry and ABPI …
Merck suffers brain cancer reverse
February 26, 2013Sales and Marketing Merck, cilengitide
Merck’s oncology programme has suffered a setback as a Phase III trial of its investigational integrin inhibitor cilengitide failed in …
Probe launched as deaths prompt Omontys recall
February 26, 2013Manufacturing and Production Affymax, Takeda, omontys, recall
Reports of three fatal reactions linked to administration of Takeda and Affymax’ Omontys anaemia treatment have led to a recall …
Elan sceptical of Royalty
February 26, 2013Sales and Marketing Elan, FDA, Tysabri, royalty pharma
Elan Corporation has poured tepid water on private equity firm Royalty Pharma’s putative offer this week for the Irish biotech …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
